• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Stock Exchange>Frankfurt Stock Exchange

Frankfurt Stock Exchange

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson

    MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson

  2. Evotec Achieves Important Milestone in TargetAD Collaboration with Janssen in Alzheimer's Disease

    Evotec Achieves Important Milestone in TargetAD Collaboration with Janssen in Alzheimer's Disease

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.